0 CHECKOUT

Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verifi, VisibiliT and Others) - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 - 2022

  • ID: 3250508
  • June 2015
  • Region: Global
  • 112 Pages
  • Transparency Market Research
North America held the largest share of the global NIPT market in terms of revenue as well as volume in 2013

FEATURED COMPANIES

  • Ariosa Diagnostics, Inc.
  • Berry Genomics Co., Ltd.
  • BGI Diagnostics
  • Illumina, Inc.
  • LifeCodexx AG
  • Natera, Inc.
  • MORE

Non-invasive prenatal testing (NIPT) is used for screening pregnant women at high risk of developing fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X), and also for fetal sex determination. Until recently, amniocentesis, chorionic villus sampling (CVS), maternal serum screening and nuchal translucency (NT) scan were the primary diagnostic and screening methods for chromosomal abnormalities. Advent of non-invasive prenatal test is poised to eliminate disadvantages associated with these methods, such as low rate of accuracy with maternal serum screening and NT scan, and risk of miscarriage with invasive amniocentesis and CVS procedures. This report on non-invasive prenatal testing market studies the current market scenario and future potential for non-invasive prenatal tests globally. The major non-invasive prenatal tests studied in this report are BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verifi, VisibiliT and others (IONA, NACE, etc.). These tests have been extensively analyzed on the basis of factors such as the technology used, cost to patients, READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Ariosa Diagnostics, Inc.
  • Berry Genomics Co., Ltd.
  • BGI Diagnostics
  • Illumina, Inc.
  • LifeCodexx AG
  • Natera, Inc.
  • MORE

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Assumptions
1.3.2 Sources
1.3.2.1 Secondary Research
1.3.2.2 Primary Research
1.3.3 Models

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Non-Invasive Prenatal Testing (NIPT) Market (2013 & 2022)
2.2 Global Non-Invasive Prenatal Testing Market, by Test, 2013 (USD Million)
2.3 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2013 & 2022 (Value %)
2.4 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Volume, by Geography, 2013 & 2022 (Volume %)

Chapter 3 Global Non-Invasive Prenatal Testing Market Overview
3.1 Introduction
3.2 Major Chromosomal Aneuploidies and their Incidence Rate
3.2.1 Down Syndrome
3.2.2 Edwards Syndrome
3.2.3 Patau Syndrome
3.2.4 Turner Syndrome
3.2.5 Klinefelter Syndrome
3.2.6 Jacobs Syndrome
3.2.7 Triple X Syndrome
3.3 Technological Approach for NIPT
3.4 Patent Landscape
3.4.1 Major Patents issued to Sequenom, Inc.
3.4.2 Major Patents issued to Ariosa Diagnostics, Inc.
3.4.3 Major Patents issued to Natera, Inc.
3.4.4 Major Patents issued to Verinata Health, Inc. (Illumina, Inc.)
3.4.5 Major Patents issued to Cellscape Corporation
3.4.6 Others
3.5 Market Drivers
3.5.1 High incidence rate of babies born with Down syndrome
3.5.2 Globally rising average maternal age
3.5.3 Increasing demand for early and non-invasive fetal testing procedures
3.6 Market Restraints
3.6.1 Regulatory guidelines and ethical hurdles
3.6.2 Limitations of NIPT
3.6.3 Availability of other screening and testing methods
3.7 Market Opportunities
3.7.1 Capitalizing on the potential presented by the emerging markets of Asia
3.8 Porter’s Five Force Analysis: Global Non-Invasive Prenatal testing Market
3.8.1 Bargaining power of suppliers
3.8.2 Bargaining power of buyers
3.8.3 Threat of substitutes
3.8.4 Threat of new entrants
3.8.5 Competitive rivalry
3.9 Market Attractiveness Analysis: Global Non-Invasive Prenatal Testing Market, by Geography
3.9.1 Market Attractive Analysis: Global Non-Invasive Prenatal Testing Market, by Geography
3.10 Competitive Landscape
3.10.1 Market Share Analysis, by Key Players, 2013 (%)
3.10.2 Non-Invasive Prenatal Testing: Market Share, by Key Players, 2013(%)

Chapter 4 Global Non-Invasive Prenatal Testing Market Revenue (USD Million) and Volume (Number of Tests Performed), by Test
4.1 Overview
4.1.1 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 - 2022 (USD Million)
4.1.2 Global Non-Invasive Prenatal Testing Market Volume, by Test, 2012 - 2022 (Number of Tests Performed)
4.1.3 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2013 & 2022 (Value %)
4.1.4 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Volume, by Test, 2013 & 2022 (Volume %)
4.2 BambniTest
4.2.1 Global BambniTest Test Market Revenue, 2012 - 2022 (USD Million)
4.2.2 Global BambniTest Test Market Volume, 2012 - 2022 (Number of Tests Performed)
4.3 Harmony Prenatal Test
4.3.1 Global Harmony Test Market Revenue, 2012 - 2022 (USD Million)
4.3.2 Global Harmony Test Market Volume, 2012 - 2022 (Number of Tests Performed)
4.4 informaSeq Prenatal Test
4.4.1 Global informaSeq Test Market Revenue, 2014 - 2022 (USD Million)
4.4.2 Global informaSeq Test Market Volume, 2014 - 2022 (Number of Tests Performed)
4.5 MaterniT21 PLUS
4.5.1 Global MaterniT21 PLUS Test Market Revenue, 2012 - 2022 (USD Million)
4.5.2 Global MaterniT21 PLUS Test Market Volume, 2012 - 2022 (Number of Tests Performed)
4.6 Non-invasive Fetal Trisomy (NIFTY) Test
4.6.1 Global NIFTY Test Market Revenue, 2012 - 2022 (USD Million)
4.6.2 Global NIFTY Test Market Volume, 2012 - 2022 (Number of Tests Performed)
4.7 Panorama Test
4.7.1 Global Panorama Test Market Revenue, 2012 - 2022 (USD Million)
4.7.2 Global Panorama Test Market Volume, 2012 - 2022 (Number of Tests Performed)
4.8 PrenaTest
4.8.1 Global PrenaTest Test Market Revenue, 2012 - 2022 (USD Million)
4.8.2 Global PrenaTest Test Market Volume, 2012 - 2022 (Number of Tests Performed)
4.9 verifi
4.9.1 Global verifi Test Market Revenue, 2012 - 2022 (USD Million)
4.9.2 Global verifi Test Market Volume, 2012 - 2022 (Number of Tests Performed)
4.10 VisibiliT Test
4.10.1 Global VisibiliT Test Market Revenue, 2014 - 2022 (USD Million)
4.10.2 Global VisibiliT Test Market Volume, 2014 - 2022 (Number of Tests Performed)
4.11 Others
4.11.1 Global Other Tests Market Revenue, 2014 - 2022 (USD Million)
4.11.2 Global Other Tests Market Volume, 2014 - 2022 (Number of Tests Performed)

Chapter 5 Global Non-Invasive Prenatal Testing Market Revenue (USD Million) and Volume (Number of Tests Performed), by Geography
5.1 Overview
5.1.1 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 - 2022 (USD Million)
5.1.2 Global Non-Invasive Prenatal Testing Market Volume, by Geography, 2012 - 2022 (Number of Tests Performed)
5.2 North America
5.2.1 North America Non-Invasive Prenatal Testing Market Revenue, 2012 - 2022 (USD Million)
5.2.2 North America Non-Invasive Prenatal Testing Market Volume, 2012 - 2022 (Number of Tests Performed)
5.3 Europe
5.3.1 Europe Non-Invasive Prenatal Testing Market Revenue, 2012 - 2022 (USD Million)
5.3.2 Europe Non-Invasive Prenatal Testing Market Volume, 2012 - 2022 (Number of Tests Performed)
5.4 Asia-Pacific
5.4.1 Asia-Pacific Non-Invasive Prenatal Testing Market Revenue, 2012 - 2022 (USD Million)
5.4.2 Asia-Pacific Non-Invasive Prenatal Testing Market Volume, 2012 - 2022 (Number of Tests Performed)
5.5 Rest of the World (RoW)
5.5.1 RoW Non-Invasive Prenatal Testing Market Revenue, 2012 - 2022 (USD Million)
5.5.2 RoW Non-Invasive Prenatal Testing Market Volume, 2012 - 2022 (Number of Tests Performed)

Chapter 6 Recommendations
6.1 Focus on improving technology in order to increase the accuracy, reduce the duration of result generation and price
6.2 Focus on forming alliances with diagnostic service providers in Latin American and Asia-Pacific countries
6.3 Mergers and acquisitions

Chapter 7 Company Profiles
7.1 Ariosa Diagnostics, Inc.
7.1.1 Company Overview
7.1.2 Financial Overview
7.1.3 Product Portfolio
7.1.4 Business Strategies
7.1.5 Recent Developments
7.2 Berry Genomics Co., Ltd.
7.2.1 Company Overview
7.2.2 Financial Overview
7.2.3 Product Portfolio
7.2.4 Business Strategies
7.2.5 Recent Developments
7.3 BGI Diagnostics
7.3.1 Company Overview
7.3.2 Financial Overview
7.3.3 Product Portfolio
7.3.4 Business Strategies
7.3.5 Recent Developments
7.4 Illumina, Inc.
7.4.1 Company Overview
7.4.2 Financial Overview
7.4.3 Product Portfolio
7.4.4 Business Strategies
7.4.5 Recent Developments
7.5 Laboratory Corporation of America Holdings (LabCorp)
7.5.1 Company Overview
7.5.2 Financial Overview
7.5.3 Product Portfolio
7.5.4 Business Strategies
7.5.5 Recent Developments
7.6 LifeCodexx AG
7.6.1 Company Overview
7.6.2 Financial Overview
7.6.3 Product Portfolio
7.6.4 Business Strategies
7.6.5 Recent Developments
7.7 Natera, Inc.
7.7.1 Company Overview
7.7.2 Financial Overview
7.7.3 Product Portfolio
7.7.4 Business Strategies
7.7.5 Recent Developments
7.8 Sequenom, Inc.
7.8.1 Company Overview
7.8.2 Financial Overview
7.8.3 Product Portfolio
7.8.4 Business Strategies
7.8.5 Recent Developments

List of Figures:
Fig. 1 Non-Invasive Prenatal Testing: Market Segmentation
Fig. 2 Global Non-Invasive Prenatal Testing Market, by Test, 2013 (USD Million)
Fig. 3 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2013 & 2022 (Value %)
Fig. 4 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Volume, by Geography, 2013 & 2022 (Volume %)
Fig. 5 Porter’s Five Force Analysis: Global Non-Invasive Prenatal Testing Market
Fig. 6 Market Attractiveness Analysis: Global Non-Invasive Prenatal Testing Market, by Geography
Fig. 7 Non-Invasive Prenatal Testing: Market Share, by Key Players, 2013 (%)
Fig. 8 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2013 & 2022 (Value %)
Fig. 9 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Volume, by Test, 2013 & 2022 (Volume %)
Fig. 10 Global BambniTest Test Market Revenue, 2012 - 2022 (USD Million)
Fig. 11 Global BambniTest Test Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 12 Global Harmony Test Market Revenue, 2012 - 2022 (USD Million)
Fig. 13 Global Harmony Test Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 14 Global informaSeq Test Market Revenue, 2014 - 2022 (USD Million)
Fig. 15 Global informaSeq Test Market Volume, 2014 - 2022 (Number of Tests Performed)
Fig. 16 Global MaterniT21 PLUS Test Market Revenue, 2012 - 2022 (USD Million)
Fig. 17 Global MaterniT21 PLUS Test Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 18 Global NIFTY Test Market Revenue, 2012 - 2022 (USD Million)
Fig. 19 Global NIFTY Test Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 20 Global Panorama Test Market Revenue, 2012 - 2022 (USD Million)
Fig. 21 Global Panorama Test Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 22 Global PrenaTest Test Market Revenue, 2012 - 2022 (USD Million)
Fig. 23 Global PrenaTest Test Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 24 Global verifi Test Market Revenue, 2012 - 2022 (USD Million)
Fig. 25 Global verifi Test Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 26 Global VisibiliT Test Market Revenue, 2014 - 2022 (USD Million)
Fig. 27 Global VisibiliT Test Market Volume, 2014 - 2022 (Number of Tests Performed)
Fig. 28 Global Other Tests Market Revenue, 2014 - 2022 (USD Million)
Fig. 29 Global Other Tests Market Volume, 2014 - 2022 (Number of Tests Performed)
Fig. 30 North America Non-Invasive Prenatal Testing Market Revenue, 2012 - 2022 (USD Million)
Fig. 31 North America Non-Invasive Prenatal Testing Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 32 Europe Non-Invasive Prenatal Testing Market Revenue, 2012 - 2022 (USD Million)
Fig. 33 Europe Non-Invasive Prenatal Testing Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 34 Asia-Pacific Non-Invasive Prenatal Testing Market Revenue, 2012 - 2022 (USD Million)
Fig. 35 Asia-Pacific Non-Invasive Prenatal Testing Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 36 RoW Non-Invasive Prenatal Testing Market Revenue, 2012 - 2022 (USD Million)
Fig. 37 RoW Non-Invasive Prenatal Testing Market Volume, 2012 - 2022 (Number of Tests Performed)
Fig. 38 LabCorp: Annual Revenue, 2011 - 2013 (USD Million)
Fig. 39 Sequenom, Inc.: Annual Revenue, by Segment, 2011 - 2013 (USD Million)

List of Tables:
Table 1 Market Snapshot: Global Non-Invasive Prenatal Testing (NIPT) Market (2013 & 2022)
Table 2 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 - 2022 (USD Million)
Table 3 Global Non-Invasive Prenatal Testing Market Volume, by Test, 2012 - 2022 (Number of Tests Performed)
Table 4 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 - 2022 (USD Million)
Table 5 Global Non-Invasive Prenatal Testing Market Volume, by Geography, 2012 - 2022 (Number of Tests Performed)
Table 6 Ariosa Diagnostics, Inc.: Expenses & Revenue, 2011 - 2013 (USD Thousand)
Table 7 Sequenom, Inc.: Expenses & Revenue, 2011 - 2013 (USD Million)

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Ariosa Diagnostics, Inc.
  • Berry Genomics Co., Ltd.
  • BGI Diagnostics
  • Illumina, Inc.
  • LifeCodexx AG
  • Natera, Inc.
  • MORE

Non-invasive prenatal testing is increasingly being adopted by high-risk pregnant women for screening common fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X). Non-invasiveness, accuracy, and safety are the major factors attributed to the popularity of these tests among gynecologists and expecting mothers compared to invasive tests such as chorionic villus sampling (CVS) and amniocentesis. MaterniT21 (now known as MaterniT21 PLUS) was the first NIPT launched in October 2011 by U.S.-based Sequenom, Inc. Since then, it has led the market, accounting for the largest share in terms of revenue as well as volume (number of tests performed in a year). However, BGI’s NIFTY is expected to outperform MaterniT21 PLUS in terms of volume in the global market by the end of 2014. Sequenom, Inc. is likely to maintain its leadership position in North America through 2022. Harmony, verifi, Panorama, informaSeq, VisibiliT, PrenaTest, and BambniTest are the other commercially available NIPTs for detecting chromosomal abnormalities.

The exponential growth of the NIPT market is supported by factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT, and shifting trend toward child bearing at advanced maternal age (35 years or older). Maternal age is closely associated with the risk of developing a fetus with chromosomal abnormalities; hence, rising maternal age is likely to contribute to the increasing incidence of babies born with chromosomal aneuploidies. According to Down Syndrome Education (DSE), the incidence rate for Down syndrome is one in every 830 child births (around 4,700 annually) in the U.S., while the incidence rate is one in every 920 babies born (around 9,000 annually) in Europe, indicating a large potential consumer base for NIPT. Conventional invasive prenatal genetic tests such as amniocentesis and chorionic villus sampling (CVS) are associated with the risk of miscarriage; hence, these are being replaced with new non-invasive prenatal tests. These new NIPTs are based on the analysis of cell-free DNA floating in the maternal plasma and pose no risk of miscarriage.

North America held the largest share of the global NIPT market in terms of revenue as well as volume in 2013, accounting for 58.8% and 51.0%, respectively, of the market. Major players domiciled in the U.S. and relatively high awareness levels about NIPT in North America are the key factors attributed to the region’s leadership position. In Europe, market growth largely depends upon increasing penetration of these U.S.-based test developers and increase in acceptance of these tests. Japan, Australia, China, and India represent high growth potential markets in Asia-Pacific. Large population of women preferring late pregnancy is likely to act as a major driver of the NIPT market in the region. The NIPT market in China is dominated by two local players: BGI Diagnostics and Berry Genomics. In addition, the recent CFDA approval for BambniTest would propel the growth of the market in this region.

Sequenom, Inc., Illumina, Inc. (Verinata Health, Inc.), Ariosa Diagnostics, Natera, Inc., BGI Health, LifeCodexx AG, LabCorp, and Berry Genomics are the key players competing in the non-invasive prenatal testing market. These players operate by marketing their proprietary non-invasive prenatal tests by forming alliances with hospitals, clinical laboratories, and physician offices.

Note: Product cover images may vary from those shown

- Ariosa Diagnostics, Inc.
- BGI Diagnostics
- Berry Genomics Co., Ltd.
- Illumina, Inc.
- Laboratory Corporation of America Holdings (LabCorp)
- LifeCodexx AG
- Natera, Inc.
- Sequenom, Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • STILLE Surgical Instruments
  • Alcon Incorporated
  • Hoya Surgical Optics, Inc.
  • Hollister Inc.
  • PerkinElmer, Inc.
  • Cyberonics, Inc.